Vice President
Pfizer, Inc.
Hul, Massachusetts, United States
Tom joined Pfizer in 2017 as Vice President of Discovery in the Inflammation and Immunology Research Unit located in Cambridge, MA, where he leads a team of scientists focusing on autoimmune, inflammatory, and fibrotic diseases in the areas Rheumatology, Dermatology, and Gastroenterology. Members of his team also collaborate with the Oncology, Metabolic/Cardiovascular, anti-infectives, and Rare Diseases research units at Pfizer. He also serves as the director of Pfizer’s postdoctoral program. Prior to joining Pfizer in July 2017, Tom was the Chief of the Immunopathogenesis Section at NIAID, NIH in Bethesda, MD for 15 years, where he led a team of scientists focused on type 2 and fibrotic diseases in various organ systems, including the liver, intestine, and lung. He received his Ph.D. from the Department of Medical Microbiology and Immunology at the University of Wisconsin, in Madison, Wisconsin. He has published over 250 research articles in many top tier journals including Nature, Science, Nature Medicine, Sci. Transl. Med, and Immunity, and according to Google Scholars, his H-index in 2023 was 118. He has served as an advisory editor for the Journal of Experimental Medicine and consulting editor for the Journal of Clinical Investigation for many years. For the past eight years, Thomson Reuters/Clarivate Analytics has included Dr. Wynn among their list of “Highly Cited Researchers” in the field of Immunology and in 2021 Stanford-Elsevier BV’s science-wide author database of standardized citation indicators ranked Dr. Wynn at 836 among the 100,000 scientists in the 2% percentile rank and above world-wide.
Disclosure information not submitted.
Advances, Challenges, and New Therapeutic Strategies for Fibrotic Disease
Thursday, June 22, 2023
9:00 AM - 9:30 AM
